204 related articles for article (PubMed ID: 18159033)
1. Washout period for immune-modifying drugs before natalizumab therapy.
Ilanjian H; Shane R
Am J Health Syst Pharm; 2008 Jan; 65(1):18-9. PubMed ID: 18159033
[No Abstract] [Full Text] [Related]
2. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
3. Balancing risk and reward: the question of natalizumab.
Hauser SL; Johnston SC
Ann Neurol; 2009 Sep; 66(3):A7-8. PubMed ID: 19810091
[No Abstract] [Full Text] [Related]
4. Quantitative risk-benefit analysis of natalizumab.
Thompson JP; Noyes K; Dorsey ER; Schwid SR; Holloway RG
Neurology; 2008 Jul; 71(5):357-64. PubMed ID: 18663181
[TBL] [Abstract][Full Text] [Related]
5. Use of natalizumab in multiple sclerosis: current perspectives.
Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab in Multiple Sclerosis: Long-Term Management.
Clerico M; Artusi CA; Liberto AD; Rolla S; Bardina V; Barbero P; Mercanti SF; Durelli L
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468254
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
8. Multiple sclerosis, natalizumab, and PML: helping patients decide.
Rudick RA
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S18-23. PubMed ID: 22123928
[TBL] [Abstract][Full Text] [Related]
9. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
[TBL] [Abstract][Full Text] [Related]
10. PML: underdiagnosed in MS patients on natalizumab.
Steiner I
Lancet Neurol; 2010 Jun; 9(6):564; author reply 564-5. PubMed ID: 20494319
[No Abstract] [Full Text] [Related]
11. How Tysabri survived.
Huggett B
Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis woes.
Nat Neurosci; 2005 Jul; 8(7):837. PubMed ID: 16136665
[No Abstract] [Full Text] [Related]
13. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
14. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.
Anton R; Haas M; Arlett P; Weise M; Balabanov P; Mazzaglia G; Prieto L; Keller-Stanislawski B; Raine J
Clin Pharmacol Ther; 2017 Aug; 102(2):283-289. PubMed ID: 28001298
[TBL] [Abstract][Full Text] [Related]
15. The return of natalizumab: weighing benefit against risk.
Goodin D
Lancet Neurol; 2006 May; 5(5):375-7. PubMed ID: 16632301
[No Abstract] [Full Text] [Related]
16. Treating multiple sclerosis with natalizumab.
Iaffaldano P; Lucchese G; Trojano M
Expert Rev Neurother; 2011 Dec; 11(12):1683-92. PubMed ID: 22091593
[TBL] [Abstract][Full Text] [Related]
17. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
Heesen C; Kleiter I; Nguyen F; Schäffler N; Kasper J; Köpke S; Gaissmaier W
Mult Scler; 2010 Dec; 16(12):1507-12. PubMed ID: 20826527
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
[TBL] [Abstract][Full Text] [Related]
19. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
20. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
